- ADA 2022 – On the occasion of the 2022 American Diabetes Association Scientific Sessions, Diabeloop, a leader in therapeutic AI applied to insulin delivery and SOOIL Development Company, leader in superior diabetes therapy announced that they entered into global development and commercial agreements.
- Technical integration to be pursued and expanded
With these agreements, Diabeloop and SOOIL Development Company re-establish their commitment to work together by combining their technologies and expertise.
Also Read: RxBIO Launches Neogen Plasma Skin Rejuvenation in the USA – Neogen Plasma Brings a Unique Solution
The cooperation between the two companies was initiated in February 2020 with the launch of a large clinical study, including 9 University hospitals and 184 patients using DBLG1, Diabeloop’s i-controller and SOOIL’s DANA-i ACE pump. The study was unfortunately affected by the COVID-19 pandemic, however, the companies have continued to forge ahead with their respective product development roadmaps. Combining forces has enhanced the evolution of their business opportunities in a global manner.
Diabeloop, pioneer in therapeutic artificial intelligence applied to diabetes management and SOOIL Development Company, one of the leading established players in the insulin pump therapy market, announce global development agreements which will address four key areas of collaboration.
“We are addressing a fast-moving market, asking us to make constant adaptations. Our products have received outstanding feedback from patients and doctors alike, while demonstrating fast growth across Europe. Our reinforced partnership with SOOIL Development Company is one of the ways to make our products available to patients beyond Europe. These agreements offer high-potential perspectives and a promising international collaboration for our two companies,” comments Erik Huneker, CEO and co-founder of Diabeloop.
Pursuing the technical integration of the Dana-i pump within DBLG1 System will be the entry point of this newfound collaboration between the two companies.
The extended partnership with SOOIL Development Company will enable Diabeloop to continue its international expansion beyond Europe and support its sustained growth. This strategy will help drive towards the following main business objectives:
1) Entering the American market with an approved Automated Insulin Delivery solution is an important goal for both companies. A clinical trial will be performed to meet the requirements of the US health authorities, allowing the two partners to submit an application for Diabeloop’s DBLG1 AID solution with SOOIL’s Dana-i insulin pump to the FDA.
2) The companies plan to make DBLG1 System with the Dana-i pump available in the European market. Obtaining the CE marking under the European Medical Device Regulation (MDR) will be the first main step. Not only does this follow the interoperability strategy of Diabeloop, it aligns with a firm belief that having a choice matters for people living with diabetes as well as health care professionals.